2025
Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients An Updated Meta-Analysis of Randomized Controlled Trials
Reddy R, Howard J, Mack M, Reardon M, Jørgensen T, Hørsted Thyregod H, Toff W, Van Mieghem N, Vora A, Makkar R, Kapadia S, Forrest J, Leon M, Ahmad Y. Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients An Updated Meta-Analysis of Randomized Controlled Trials. Journal Of The American College Of Cardiology 2025, 85: 926-940. PMID: 40044297, DOI: 10.1016/j.jacc.2024.12.031.Peer-Reviewed Original ResearchConceptsSurgical aortic valve replacementTranscatheter aortic valve replacementLower-risk patientsAortic valve replacementPooled survival analysisValve replacementIndividual participant dataPairwise meta-analysesFollow-upMeta-analysis of randomized controlled trialsLonger-term clinical outcomesReduced hazard of deathSevere aortic stenosisFixed effect assumptionsComposite of deathLonger-term follow-upAll-cause deathMean survival time modelsMeta-analysesHazard of deathRate of strokeRandomized Controlled TrialsSurvival time modelFrailty termProportional odds model
2024
Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials
Reddy R, Howard J, Reardon M, Thyregod H, Jorgensen T, Toff W, Forrest J, Leon M, Ahmad Y. Transcatheter versus surgical aortic valve replacement in lower-risk patients: an updated meta-analysis of randomised controlled trials. European Heart Journal 2024, 45: ehae666.2456. DOI: 10.1093/eurheartj/ehae666.2456.Peer-Reviewed Original ResearchLower-risk patientsIndividual patient dataFollow-upNo significant differenceClinical outcomesPairwise random-effects meta-analysesNew-onset atrial fibrillationLong-term clinical outcomesSurgical aortic valve replacementKaplan-Meier survival curvesMeta-analysis of randomised controlled trialsLow-surgical riskMeta-analysesAortic valve reinterventionReconstructed individual patient dataLow surgical riskAortic valve replacementFollow-up durationSevere aortic stenosisMeta-analysisSignificant differenceCox proportional hazards regressionComposite of deathKaplan-Meier plotsLonger-term follow-upBrief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV
Coburn S, Pimentel N, Leyden W, Kitahata M, Moore R, Althoff K, Gill M, Lang R, Horberg M, D'Souza G, Hussain S, Dubrow R, Novak R, Rabkin C, Park L, Sterling T, Neugebauer R, Silverberg M, AIDS F. Brief Report: Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors and the Risk of Cancer Among People With HIV. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2024, 96: 393-398. PMID: 39720558, PMCID: PMC11665951, DOI: 10.1097/qai.0000000000003436.Peer-Reviewed Original ResearchNon-AIDS-defining cancersAIDS-defining cancersCancer riskAntiretroviral therapyAntiretroviral therapy classNorth American AIDS Cohort CollaborationCompare cancer riskCancer risk differencesLoss to follow-upInfection-related cancersFollow-upMarginal structural modelsIncident cancerIndividual cancer typesAntiretroviral therapy initiationLonger-term follow-upDuration of follow-upCohort CollaborationCohort studyHazard ratioRisk differenceMonths follow-upPP trialINSTI-based ARTPWH
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply